卡铂联合吉西他滨±凡德他尼一线治疗不适合顺铂的晚期尿路上皮癌:随机II期TOUCAN试验
TOUCAN双盲安慰剂对照II期试验纳入82例不适合顺铂的晚期尿路上皮癌患者,随机接受卡铂+吉西他滨联合凡德他尼或安慰剂一线治疗。凡德他尼组与安慰剂组中位PFS分别为6.8和8.8个月(HR 1.07,95%CI 0.65-1.76;P=0.71),中位OS分别为10.8和13.8个月(HR 1.41,95%CI 0.79-2.52;P=0.88),无证据表明凡德他尼改善临床结局。
要点
- 凡德他尼联合卡铂+吉西他滨未改善不适合顺铂的晚期尿路上皮癌患者的PFS或OS。
- 凡德他尼组和安慰剂组≥3级毒性发生率分别为80%和76%。
- 研究数据不支持凡德他尼作为该人群一线治疗选择。
核心结论
- 无证据表明凡德他尼在此 setting 中改善临床结局,不支持其作为不适合顺铂的晚期尿路上皮癌患者的一线治疗选择。
研究设计与样本
- TOUCAN双盲、安慰剂对照、随机II期试验,2011至2014年英国16家医院纳入82例不适合顺铂的晚期尿路上皮癌患者,1:1随机接受凡德他尼(n=40)或安慰剂(n=42)。
- 治疗方案为每21天重复、共6周期的静脉卡铂(目标AUC 4.5,第1天)和吉西他滨(1000 mg/m2,第1天和第8天),联合口服凡德他尼100 mg每日一次或安慰剂。
主要发现
- 凡德他尼组和安慰剂组≥3级毒性发生率分别为80%(n=32)和76%(n=32)。
- 凡德他尼组和安慰剂组中位PFS分别为6.8和8.8个月(HR 1.07,95%CI 0.65-1.76;P=0.71)。
- 凡德他尼组和安慰剂组中位OS分别为10.8和13.8个月(HR 1.41,95%CI 0.79-2.52;P=0.88)。
- 凡德他尼组和安慰剂组影像学缓解率分别为50%和55%。
- 25例患者(30%)完成了全部6周期分配治疗。
临床怎么用
- 对于不适合顺铂的晚期尿路上皮癌患者,不应在卡铂+吉西他滨基础上常规联合凡德他尼。
局限性
- 样本量较小(82例),仅25例(30%)完成6周期治疗,可能影响耐受性和疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy and tolerability of the dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first-line treatment of patients with advanced transitional cell carcinoma urothelial cancer (UC) who were unsuitable for cisplatin. PATIENTS AND METHODS: From 2011 to 2014, 82 patients were randomised from 16 hospitals across the UK into the TOUCAN double-blind, placebo-controlled randomised Phase II trial, receiving six 21-day cycles of intravenous carboplatin (target area under the concentration versus time curve 4.5, day 1) and gemcitabine (1000 mg/m2 days 1 and 8) combined with either oral vandetanib 100 mg or placebo (once daily). Progression-free survival (PFS; primary endpoint), adverse events, tolerability and feasibility of use, objective response rate and overall survival (OS) were evaluated. Intention-to-treat and per-protocol analyses were used to analyse the primary endpoint. RESULTS: The 82 patients were randomised 1:1 to vandetanib (n = 40) or placebo (n = 42), and 25 patients (30%) completed six cycles of all allocated treatment. Toxicity Grade ≥3 was experienced in 80% (n = 32) and 76% (n = 32) of patients in the vandetanib and placebo arms, respectively. The median PFS was 6.8 and 8.8 months for the vandetanib and placebo arms, respectively (hazard ratio [HR] 1.07, 95% confidence interval [CI] 0.65-1.76; P = 0.71); the median OS was 10.8 vs 13.8 months (HR 1.41, 95% CI 0.79-2.52; P = 0.88); and radiological response rates were 50% and 55%. CONCLUSION: There is no evidence that vandetanib improves clinical outcome in this setting. Our present data do not support its adoption as the regimen of choice for first-line treatment in patients with UC who were unfit for cisplatin.
引用
- Jones R, Crabb S, Chester J, et al. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU Int. 2020. PMID: 32336008. doi:10.1111/bju.15096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。